General Biotechnology

How Brand-Name Drug Companies Delay Generic Competition: Product Hopping, Patent Thickets, and Market Exclusivity Tactics Explained

Generic drugs are supposed to be the systems pressure valveyet a growing body of evidence suggests the valve is getting throttled.
For patients, payers, and policymakers, the cost of delay is measured in months and years. For innovators, the incentiv…

How Brand-Name Drug Companies Delay Generic Competition: Product Hopping, Patent Thickets, and Market Exclusivity Tactics Explained Read Post »

Biotechblog
Scroll to Top